Navigation Links
Nexavar Approved in Japan for the Treatment of Advanced Liver Cancer
Date:5/20/2009

- First and only oral targeted therapy to significantly improve overall survival in patients with the disease -

WAYNE, N.J. and EMERYVILLE, Calif., May 20 /PRNewswire-FirstCall/ -- Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that the Ministry of Health, Labour and Welfare (MHLW) in Japan has approved Nexavar(R) (sorafenib) tablets for the treatment of patients with unresectable hepatocellular carcinoma (HCC), a type of liver cancer that accounts for 95 percent of all liver cancer cases in Japan(1). Nexavar is also currently available in Japan as an approved treatment for unresectable or metastatic renal cell carcinoma (RCC).

The approval in Japan was based on the international, Phase 3 double-blind, placebo-controlled Sorafenib HCC Assessment Randomized Protocol (SHARP) study that evaluated more than 800 patients who received no prior systemic therapy. The study found that Nexavar improved overall survival in patients with HCC by 44 percent (HR=0.69; p=0.0006) versus placebo. Based on SHARP results, Nexavar is currently approved in more than 70 countries for liver cancer, including the U.S. and countries in Europe.

"Liver cancer is one of the leading causes of cancer-related deaths in Japan, and the incidence is continuing to rise," said Gunnar Riemann, member of the Executive Committee of Bayer HealthCare. "We are pleased with today's approval and what it may mean for liver cancer patients in Japan and their families who now have a therapy like Nexavar that has the potential to extend their lives."

In Japan, approximately 40,000 people are diagnosed with liver cancer each year and approximately 36,000 die from the disease, making primary liver cancer the third leading cause of cancer-related death in Japan.(2)

Hepa
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals; Onyx Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. New Analyses Confirm Nexavars Efficacy and Safety in Multiple Patient Subsets With Liver Cancer
2. Onyx Pharmaceuticals Announces a Teleconference and Webcast to Provide an Update on Nexavar; Previously Announced Fourth Quarter and Full Year 2007 Financial Results Teleconference Rescheduled
3. Career Step Approved to Train Military Spouses with Department of Defense CAA Funds
4. Takeda to Acquire IDM Pharma, Adding MEPACT(R) (Mifamurtide), the First Treatment Approved for Osteosarcoma in More Than 20 Years, to Its Oncology Franchise
5. IQAir HealthPro Plus Wins Parent Tested Parent Approved Seal of Approval Award
6. Nektar Announces UCBs Cimzia(R) Approved by U.S. FDA for Adult Patients Suffering From Moderate to Severe Rheumatoid Arthritis
7. UCBs CIMZIA(R) (certolizumab pegol) Approved by the U.S. FDA for Adult Patients Suffering From Moderate to Severe Rheumatoid Arthritis
8. MedClean Technologies, Inc. Approved in New Jersey
9. GADA Points to Safety of FDA Approved Generics in Wake of Wellington Polo Horse Deaths from Compounded Drugs
10. DRAXIMAGE(R)s generic Sestamibi Approved for launch in USA
11. New Botox(R) Alternative Dysport(TM) FDA Approved, Ready to Rumble
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... May 04, 2015 In a continuing ... for substance absue, Per Wickstrom, the founder of Choices ... Lounge and the “Salute to the Oscars” celebration ... on the top floor of the luxurious Beverly Hilton ... top producer of sustainable product placement in TV and ...
(Date:5/4/2015)... Each year, the Susan G. Komen organization hosts ... for breast cancer. This year, Dr. Mark Deutsch and his ... entertainment sponsor for the 25th annual Susan G. Komen Greater ... Lenox Square Mall. , The Komen organization hopes have 10,000 ... million. Perimeter Plastic Surgery has not only taken on the ...
(Date:5/4/2015)... (PRWEB) May 04, 2015 “ LiveSchool ... monthly AppWatch, which takes a look at the latest ... and Windows. Joe Toohey, the host of AppWatch and ... viewers how this application allows teachers to reward students ... than some realize, especially in the classroom. And ...
(Date:5/4/2015)... Santa Ana, CA (PRWEB) May 04, 2015 ... and live a full life are the motivating forces behind ... by California clinical psychologist and author Amy L. Stark. , ... and the little girl next door comes from Stark’s desire ... said Stark. “I’ve been a fairy godmother to my neighbors’ ...
(Date:5/4/2015)... (PRWEB) May 04, 2015 The U.S. ... baby boomers join the ranks of senior citizens (1) ... on an already over-burdened healthcare system. Additionally, as older ... to replace them. Per the U.S. Census Bureau, the ... to increase 75% by 2050 while those 25 to ...
Breaking Medicine News(10 mins):Health News:Per Wickstrom Interviews TV and Film Star Carolyn Hennesy About Substance Abuse and Treatment 2Health News:Perimeter Plastic Surgery Sponsors 2015 Susan G. Komen Greater Atlanta "Race for the Cure" 2Health News:An Application for Teachers to Reward Students with Good Behavior Was Featured on NewsWatch Television 2Health News:Introducing New Children’s Book The Fairy Godmother Next Door 2Health News:U.S. Healthcare Worker Shortage Escalating: Sterling Warns Medical Practitioners to Rapidly Reverse Low Employee Retention 2Health News:U.S. Healthcare Worker Shortage Escalating: Sterling Warns Medical Practitioners to Rapidly Reverse Low Employee Retention 3Health News:U.S. Healthcare Worker Shortage Escalating: Sterling Warns Medical Practitioners to Rapidly Reverse Low Employee Retention 4
... Feb. 3 BeneChill, Inc. ( www.benechill.com ) ... Intra-Nasal Cooling Effectiveness) study. This randomized study will ... during resuscitation increases patient resuscitation and survival rates.The ... approval study in Europe. The company received CE ...
... Nearly three out of four Americans (71 ... cost of addiction treatment - yet most consumers ... would pay for substance abuse treatment, according to ... Hazelden, the national nonprofit organization that helps people ...
... ESRX ), one of the largest pharmacy benefit management companies ... quarter earnings,on Wednesday, February 25, 2009 after the market closes ... results on Thursday,February 26, 2009, at 10:00 a.m. Eastern Time ... call is being webcast and can be accessed at Express ...
... be avoided since most symptoms fade within 6 weeks, ... A combination of physical therapy and anti-inflammatory drugs is ... by symptomatic lumbar degenerative disc disease, according to a ... found that in 90 percent of people with low ...
... known that patients with few primary care doctor,s office ... new research indicates that even patients who see their ... study, which appears in the February issue of ... a team of researchers at UC Davis, the University ...
... allied healthcare providers, and policymakers will gather in ... Williamsburg Lodge to learn practical, clinical information on ... and innovative translational research advances that impact patient ... full program, faculty, accreditation, and registration information is ...
Cached Medicine News:Health News:BeneChill Launches European Study of Intra-Arrest Cooling 2Health News:Three-Quarters of Americans Believe Health Insurance Should Pay for Addiction Treatment, Yet Most Don't Know If Their Health Plan Covers Substance-Abuse Care, Says New Hazelden Survey 2Health News:Three-Quarters of Americans Believe Health Insurance Should Pay for Addiction Treatment, Yet Most Don't Know If Their Health Plan Covers Substance-Abuse Care, Says New Hazelden Survey 3Health News:Three-Quarters of Americans Believe Health Insurance Should Pay for Addiction Treatment, Yet Most Don't Know If Their Health Plan Covers Substance-Abuse Care, Says New Hazelden Survey 4Health News:Express Scripts Announces Fourth Quarter 2008 Earnings Conference Call 2Health News:Therapy, Meds Best for Lumbar Low Back Pain 2Health News:Study shows that primary care doctors miss opportunities to recommend colon cancer screening 2Health News:Opinion Leaders in Women’s Health To Take the Podium at the 17th Annual Congress on Women’s Health 2
(Date:5/4/2015)... Rogne Bioscience, a privately-held biotechnology company developing ... and mechanism of action data will be presented during ... (SID) Annual Meeting being held May 6-9, 2015 at ... . Logo - http://photos.prnewswire.com/prnh/20150501/213318LOGO ... novel, low MW (<1700 daltons) peptide as a topical ...
(Date:5/4/2015)... , May 4, 2015  By looking at ... to distinguish between two very different conditions that ... Theodore Henderson , MD, PhD., a ... cases, this study can help the ... therefore treatment options, for Post-Traumatic Stress Disorder (PTSD) ...
(Date:5/4/2015)... 4, 2015  CytRx Corporation (Nasdaq: CYTR ... in oncology, today announced an interim analysis from ... pairing aldoxorubicin with either gemcitabine or ifosfamide. Both ... with escalating doses of aldoxorubicin. The combinations appear ... lowest dose level of aldoxorubicin (170 mg/m2), impressive ...
Breaking Medicine Technology:Rogne Bioscience to Present Data from Topical Biologic Psoriasis Program at Upcoming SID Annual Meeting 2015 2New Medical Research Shows Brain Imaging Can Now Help Doctors Differentiate Between PTSD and Traumatic Brain Injuries 2New Medical Research Shows Brain Imaging Can Now Help Doctors Differentiate Between PTSD and Traumatic Brain Injuries 3CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 2CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 3CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 4CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 5CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 6CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 7
... HILL, N.J. and ATLANTA, Feb. 9, 2012  Glowpoint, Inc. ... provider of cloud managed video services , today ... a leader in designing and integrating operating rooms, has ... video platform for videoconferencing and broadcasting from operating rooms. ...
... Mylan Inc. (Nasdaq: MYL ) CEO Heather Bresch ... Commerce Committee at a hearing hosted by the subcommittee on ... User Fees and Further Examination of Drug Shortages." ... peace of mind in knowing that every prescription, brand or ...
Cached Medicine Technology:Stryker Communications Selects Glowpoint to Enhance IP Video Platform for Operating Rooms 2Stryker Communications Selects Glowpoint to Enhance IP Video Platform for Operating Rooms 3Mylan CEO Heather Bresch Testifies Before Congress in Support of Generic Drug User Fee Program and Urges Update of Federal Food, Drug and Cosmetic Act of 1938 to Create a Level Playing Field for Manufacturers 2Mylan CEO Heather Bresch Testifies Before Congress in Support of Generic Drug User Fee Program and Urges Update of Federal Food, Drug and Cosmetic Act of 1938 to Create a Level Playing Field for Manufacturers 3Mylan CEO Heather Bresch Testifies Before Congress in Support of Generic Drug User Fee Program and Urges Update of Federal Food, Drug and Cosmetic Act of 1938 to Create a Level Playing Field for Manufacturers 4
... incubators is available, ensuring the customers to ... specific requirements. miniTHERM incubators have a capacity ... space saving. Their size corresponds approximately to ... to stack up to three units on ...
In microbiological laboratories and for in vitro fertilization, as well as in cancer research or tissue engineering, the Heraeus CO2 incubator BBD 6220 provides the best contamination protection and ...
US Autoflow Single Chamber Stackable Water-Jacketed CO2 Inc.w/ Humidity Display and Control...
...
Medicine Products: